Literature DB >> 34817805

Designing of a Chimeric Vaccine Using EIS (Rv2416c) Protein Against Mycobacterium tuberculosis H37Rv: an Immunoinformatics Approach.

R Logesh1, V Lavanya2, Shazia Jamal1, Neesar Ahmed3.   

Abstract

Mycobacterium tuberculosis (Mtb) is a respiratory pathogen that causes tuberculosis (TB). There are a large number of proteins that are involved in the pathogenesis of TB. Stimulating the immune response against TB is very important to clear the pathogens from host. In the present study, an immunoinformatics conduit is used for designing an epitope based chimeric vaccine against TB. Enhanced intracellular survival (EIS) protein from Mtb is used for designing the chimeric vaccine. One B cell epitope, 8 cytotoxic T lymphocyte (CTL), and 6 helper T lymphocyte (HTL) epitopes were predicted based on the MHC allele binding, immunogenicity, antigenicity, allergenicity, toxicity and IFN epitopes. The selected epitopes were used for chimeric vaccine designing. Furthermore, 3D structure elucidation, structural refinement and validation of the designed chimeric vaccine were carried out. The 3D structure was used for protein-protein docking studies with Toll-like receptor 4 (TLR-4), followed by molecular dynamic simulation (MDS) and the interaction between the chimeric vaccine and TLR-4 complex was verified.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chimeric vaccine; EIS; Immunoinformatics; TLR-4; Tuberculosis

Mesh:

Substances:

Year:  2021        PMID: 34817805     DOI: 10.1007/s12010-021-03760-0

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  49 in total

Review 1.  B cells as multi-functional players during Mycobacterium tuberculosis infection and disease.

Authors:  Willem J du Plessis; Gerhard Walzl; André G Loxton
Journal:  Tuberculosis (Edinb)       Date:  2015-11-03       Impact factor: 3.131

2.  The Rate of CD4 T Cell Entry into the Lungs during Mycobacterium tuberculosis Infection Is Determined by Partial and Opposing Effects of Multiple Chemokine Receptors.

Authors:  Stella G Hoft; Michelle A Sallin; Keith D Kauffman; Shunsuke Sakai; Vitaly V Ganusov; Daniel L Barber
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 3.  Cellular and humoral immune responses during tuberculosis infection: useful knowledge in the era of biological agents.

Authors:  Andrea Matucci; Enrico Maggi; Alessandra Vultaggio
Journal:  J Rheumatol Suppl       Date:  2014-05

Review 4.  Effector and regulatory B cells: modulators of CD4+ T cell immunity.

Authors:  Frances E Lund; Troy D Randall
Journal:  Nat Rev Immunol       Date:  2010-03-12       Impact factor: 53.106

5.  The Innate Immune Response to Mycobacterium tuberculosis Infection.

Authors:  Mariëtta M Ravesloot-Chávez; Erik Van Dis; Sarah A Stanley
Journal:  Annu Rev Immunol       Date:  2021-02-26       Impact factor: 28.527

Review 6.  Immunology of tuberculosis.

Authors:  Alamelu Raja
Journal:  Indian J Med Res       Date:  2004-10       Impact factor: 2.375

Review 7.  How B cells shape the immune response against Mycobacterium tuberculosis.

Authors:  Paul J Maglione; John Chan
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

8.  Mycobacterium tuberculosis strains lacking surface lipid phthiocerol dimycocerosate are susceptible to killing by an early innate host response.

Authors:  Tracey A Day; John E Mittler; Molly R Nixon; Cullen Thompson; Maurine D Miner; Mark J Hickey; Reiling P Liao; Jennifer M Pang; Dmitry M Shayakhmetov; David R Sherman
Journal:  Infect Immun       Date:  2014-10-06       Impact factor: 3.441

9.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

10.  Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA.

Authors:  Yi Xia; Yasheen Zhou; David S Carter; Matthew B McNeil; Wai Choi; Jason Halladay; Pamela W Berry; Weimin Mao; Vincent Hernandez; Theresa O'Malley; Aaron Korkegian; Bjorn Sunde; Lindsay Flint; Lisa K Woolhiser; Michael S Scherman; Veronica Gruppo; Courtney Hastings; Gregory T Robertson; Thomas R Ioerger; Jim Sacchettini; Peter J Tonge; Anne J Lenaerts; Tanya Parish; Mrk Alley
Journal:  Life Sci Alliance       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.